

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)\*

Ultragenyx Pharmaceutical Inc.  
(Name of Issuer)

Common Stock  
(Title of Class of Securities)

90400D108  
(CUSIP Number)

December 31, 2018  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP: 90400D108

Page 1 of 4

1 NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
New Perspective Fund

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Maryland

5 SOLE VOTING POWER

NONE

6 SHARED VOTING POWER

NONE

NUMBER OF  
SHARES  
BENEFICIA  
L Y OWNED BY

7 SOLE DISPOSITIVE POWER

NONE

EACH  
REPORTING  
PERSON  
WITH:

8 SHARED DISPOSITIVE POWER

NONE

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,768,288 See Additional information in Item 4.  
Under certain circumstances, New Perspective Fund may vote the shares  
of the fund. These shares may also be reflected in a filing made by  
Capital Research Global Investors, Capital International Investors,  
and/or Capital World Investors

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
(SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

5.4%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IV

CUSIP: 90400D108

Page 2 of 4

SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

Schedule 13G  
Under the Securities Exchange Act of 1934

Amendment No. 1

Item 1(a) Name of Issuer:  
Ultragenyx Pharmaceutical Inc.

Item 1(b) Address of Issuer's Principal Executive Offices:  
60 Leveroni Court  
Novato, CA 94949

Item 2(a) Name of Person(s) Filing:  
New Perspective Fund

Item 2(b) Address of Principal Business Office or, if none,  
Residence:  
333 South Hope Street  
Los Angeles, California 90071

Item 2(c) Citizenship: N/A

Item 2(d) Title of Class of Securities:  
Common Stock

Item 2(e) CUSIP Number:  
90400D108

Item 3 If this statement is filed pursuant to sections 240.13d-1(b)  
or 240.13d-2(b) or (c), check whether the person filing is a:  
(d)  Investment company registered under section 8  
of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

Item 4 Ownership

Provide the following information regarding the aggregate  
number and percentage of the class of securities of the issuer  
identified in Item 1.

- (a) Amount beneficially owned:
- (b) Percent of class:
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote:
  - (ii) Shared power to vote or to direct the vote:
  - (iii) Sole power to dispose or to direct the disposition of:
  - (iv) Shared power to dispose or to direct the disposition of:

See page 2

New Perspective Fund, an investment company registered under  
the Investment Company Act of 1940, which is advised by Capital  
Research and Management Company ("CRMC"), is the beneficial  
owner of 2,768,288 shares or 5.4% of the 50,579,619 shares  
believed to be outstanding. CRMC manages equity assets for  
various investment companies through three divisions, Capital  
Research Global Investors, Capital World Investors, and Capital

CUSIP: 90400D108

Page 3 of 4

International Investors. These divisions generally function  
separately from each other with respect to investment research  
activities and they make investment decisions and proxy voting  
decisions for the investment companies on a separate basis.

Item 5 Ownership of Five Percent or Less of a Class. If this  
statement is being filed to report the fact that as of the date  
hereof the reporting person has ceased to be the beneficial  
owner of more than five percent of the class of securities,  
check the following: [ ]

Item 6 Ownership of More than Five Percent on Behalf of Another  
Person: N/A

Item 7 Identification and Classification of the Subsidiary Which  
Acquired the Security Being Reported on By the Parent Holding  
Company or Control Person: N/A

Item 8 Identification and Classification of Members of the Group:  
N/A

Item 9 Notice of Dissolution of Group: N/A

Item 10 Certification

By signing below, I certify that, to the best of my knowledge  
and belief, the securities referred to above were acquired and  
are held in the ordinary course of business and were not

acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 8, 2019

Signature: /s/ Michael W. Stockton  
Name/Title: Michael W. Stockton- Secretary  
New Perspective Fund

